Tech Company Financing Transactions

IM Therapeutics Funding Round

On 10/10/2019, IM Therapeutics landed $10 million in Series A funding from JDRF T1D Fund, Morningside Group and CU Healthcare Innovation Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

299 Washington St. A
Woburn, MA 01801
USA

Phone

(303) 544-2104

Website

www.imtherapeutics.com

Email Address

[email protected]

Overview

IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Nandan Padukone

        

Chief Medical Officer

Peter Gottlieb

        

Chief Scientific Officer

Aaron Michels

        

VP - R & D

Robert Perni

        

Browse more venture capital transactions:

Prev: 10/10/2019: BrainCheck venture capital transaction
Next: 10/11/2019: Myra Medical venture capital transaction

Share this article

News on VC Transactions

Our team works diligently to document all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary